|1.||Hiebert, Linda M: 1 article (01/2002)|
|2.||Wice, S M: 1 article (07/2000)|
|3.||Hiebert, L M: 1 article (07/2000)|
|4.||Ping, T: 1 article (07/2000)|
07/01/2000 - "Compared to saline, oral Logiparin reduced the incidence of thrombosis at all doses with a dose-dependent effect suggested. "
03/01/1993 - "A multicentre, double-blind, randomised trial was conducted to compare the efficacy of a low-molecular-weight (LMW) heparin, Logiparin, with that of an unfractionated (UF) heparin in the prophylactic treatment of thrombosis in patients undergoing general surgery. "
07/01/2000 - "A 50% reduction in thrombosis was observed at 0.1 mg/kg for oral Logiparin versus 7.5 mg/kg for unfractionated bovine lung heparin indicating that oral Logiparin is an effective antithrombotic agent at doses lower than unfractionated heparin. "
06/30/1986 - "In conclusion, it was found that after intravenous administration LHN-1 prevented experimental thrombosis as effectively as conventional heparin. "
01/01/2002 - "Low molecular weight heparins were effective at lower doses than unfractionated heparins where a fifty percent reduction in thrombosis was observed with 0.025 mg/kg reviparin, 0.1 mg/kg logiparin, versus 7.5 mg/kg bovine unfractionated heparin. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
09/15/1989 - "For future studies on the therapeutic effect of Logiparin in deep venous thrombosis a single dose of 150 to 200 F-XaI activity per 24 hours seems to be most suitable."
03/01/1992 - "A total of 1290 patients (Pts) undergoing general surgery were enrolled in a randomized, multicentre double-blind study in order to investigate the efficacy and safety of two different doses of a low molecular weight heparin (LMWH) (Logiparin) for the prevention of deep vein thrombosis. "
04/01/1991 - "A total of 1290 patients were enrolled in a randomized multicentre double blind study in order to investigate the use of two doses of a new low molecular weight heparin, Logiparin, in the prevention of deep vein thrombosis (DVT) in general surgery. "
04/01/1991 - "Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. "
09/15/1989 - "Treatment of deep venous thrombosis with low molecular weight heparin (LMWH-Novo, Logiparin) was carried out with two different doses of Logiparin, 75 XaI U/kg b.w. "
01/01/1988 - "From this study it was concluded that the given dose of Logiparin was safe with regard to bleeding complications. "
06/30/1986 - "Bleeding times after administration of LHN-1 and conventional heparin were determined by tail transsection in anaesthetized rats and by template bleeding in the ear of conscious pigs. "
|5.||Body Weight (Weight, Body)
03/01/1993 - "Although a correlation between plasma anti-Xa activity and body weight was observed, there is not sufficient evidence to recommend the adjustment of the Logiparin dose on patient's weight for prophylaxis in general surgery patients."
01/01/1991 - "Group A (105 patients) received Logiparin (Novo-Nordisk, Denmark) 50 mg/kg body weight once daily, and group B (105 patients) received placebo once daily. "
02/28/1989 - "35 anti-Xa units per kg of body weight of LHN-1 (Novo). "
02/01/1991 - "Patients in the heparin group received 50 IU anti-Xa per kilo body weight of Logiparin once daily, and patients in the placebo group received one daily injection of saline. "
|2.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|5.||Dalteparin (Dalteparin Sodium)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)